Correlation of Wilms' Tumor 1 Isoforms with HER2 and ER-α and its Oncogenic Role in Breast Cancer

被引:0
|
作者
Nasomyon, Tapanawan [1 ]
Samphao, Srila [2 ]
Sangkhathat, Surasak [2 ]
Mahattanobon, Somrit [2 ]
Graidist, Potchanapond [1 ]
机构
[1] Prince Songkla Univ, Fac Med, Dept Biomed Sci, Hat Yai 90110, Songkhla, Thailand
[2] Prince Songkla Univ, Fac Med, Dept Surg, Hat Yai 90110, Songkhla, Thailand
关键词
WT1; ER-alpha; HER2; breast cancer; ESTROGEN-RECEPTOR-ALPHA; SUPPRESSOR GENE WT1; GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVITY; REGULATES EXPRESSION; APOPTOSIS; OVEREXPRESSION; ACTIVATION; MECHANISM; THERAPY;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Wilms' tumor 1 (WT1) gene has different functional properties depending on the isoform type. This gene correlates with cell proliferation in various types of cancer. Here, we investigated the expression of WT1 isoforms in breast cancer tissues, and focused on the oncogenic role through estrogen receptor-alpha (ER-alpha) and human epidermal growth factor receptor 2 (HER2). Materials and Methods: Expression of WT1(17AA+) and (17AA-) was investigated in adjacent normal breast and breast cancer using Reverse transcription-polymerase chain reaction and western blotting. The correlation of WT1 isoforms with HER2 and ER-alpha was examined using MCF-7 cells stably-overexpressing WT1s and siRNA against WT1 gene. Results: The expression of WT(17AA-) was significantly found in adjacent normal breast tissues. A mixture of WT1(17AA+) and WT1(17AA-) were highly expressed in breast carcinoma tissues. MCF-7 cells overexpressing WT1+/+ and WT1+/- represented strong expression of ER-alpha and HER2. Moreover, the silencing of WT1+/+ and WT1+/- resulted in a decrease of both ER-alpha and HER2 and led to a decrease of cell numbers. Conclusion: Our results suggest that WT1(17AA+) was exhibited dominantly in breast carcinoma tissues. WT1+/+ and WT1+/- correlated with the high expression of ER-alpha and HER2, leading to cell proliferation and might be involved in cancer development and progression.
引用
收藏
页码:1333 / 1342
页数:10
相关论文
共 50 条
  • [21] Discordance of the ER- and HER2-status on disseminated tumor cells compared to the primary tumor in patients with early breast cancer
    Jaeger, B. A. S.
    Finkenzeller, C.
    Bock, C.
    Majunke, L.
    Jueckstock, J.
    Andergassen, U.
    Neugebauer, J.
    Pestka, A.
    Friedl, T.
    Jeschke, U.
    Janni, W.
    Doisneau-Sixou, S.
    Rack, B.
    CANCER RESEARCH, 2013, 73
  • [22] ER+/HER2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER-/HER2+ Breast Cancer
    Arciero, Cletus A.
    Guo, Yi
    Jiang, Renjian
    Behera, Madhusmita
    O'Regan, Ruth
    Peng, Limin
    Li, Xiaoxian
    CLINICAL BREAST CANCER, 2019, 19 (04) : 236 - 245
  • [23] HER2 Silences Tumor Suppression in Breast Cancer Cells by Switching Expression of C/EBPβ Isoforms
    Arnal-Estape, Anna
    Tarragona, Maria
    Morales, Monica
    Guiu, Marc
    Nadal, Cristina
    Massague, Joan
    Gomis, Roger R.
    CANCER RESEARCH, 2010, 70 (23) : 9927 - 9936
  • [24] GHRH-receptor as a new targetable biomarker in breast cancer and its correlation with ER/PR/HER2 status.
    Nadji, Mehrdad
    Block, Norman L.
    Schally, Andrew V.
    Lara, Jonathan F.
    Michaelson, Richard Alan
    Pulinthanathu, Rajiv
    Tortora, Matthew
    Ali, Suhail M.
    Leitzel, Kim
    Rizvi, Syed Mujtaba
    Al-Marrawi, Mhd Yaser
    Lipton, Allan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] Role of endocrine therapy in ER+/HER2(+) breast cancers
    Webber, Victoria L.
    Dixon, J. Michael
    BREAST CANCER MANAGEMENT, 2014, 3 (01) : 103 - 111
  • [26] Role of Cannabinoid Receptor CB2 in HER2 Pro-oncogenic Signaling in Breast Cancer
    Perez-Gomez, Eduardo
    Andradas, Clara
    Blasco-Benito, Sandra
    Caffarel, Maria M.
    Garcia-Taboada, Elena
    Villa-Morales, Maria
    Moreno, Estefania
    Hamann, Sigrid
    Martin-Villar, Ester
    Flores, Juana M.
    Wenners, Antonia
    Alkatout, Ibrahim
    Klapper, Wolfram
    Roecken, Christoph
    Bronsert, Peter
    Stickeler, Elmar
    Staebler, Annette
    Bauer, Maret
    Arnold, Norbert
    Soriano, Joaquim
    Perez-Martinez, Manuel
    Megias, Diego
    Moreno-Bueno, Gema
    Ortega-Gutierrez, Silvia
    Artola, Marta
    Vazquez-Villa, Henar
    Quintanilla, Miguel
    Fernandez-Piqueras, Jose
    Canela, Enric I.
    McCormick, Peter J.
    Guzman, Manuel
    Sanchez, Cristina
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (06):
  • [27] Single agent and combined targeting of PI3K, mTOR, HER2 and ER signaling in a panel of HER2+/ER+ versus HER2+/ER- breast cancer cell lines
    O'Brien, N. A.
    Nichols, C. M.
    Thomas, J.
    Conklin, D.
    Kalous, O.
    Linnartz, R.
    Di Tomasso, E.
    Hurvitz, S. A.
    Hirawat, S.
    Slamon, D. J.
    CANCER RESEARCH, 2016, 76
  • [28] Correlation of ER, PR, and HER2 at the protein and mRNA levels in Asian patients with operable breast cancer
    Chen, Chih-Jung
    Chen, Ting-Hao
    Lei, Jason
    Liang, Ji-An
    Yang, Po-Sheng
    Huang, Chiun-Sheng
    Hsieh, Chia-Ming
    Tseng, Ling-Ming
    Liu, Liang-Chih
    Cheng, Skye Hung-Chen
    Shih, Kuan-Hui
    BIOSCIENCE REPORTS, 2022, 42 (01)
  • [29] The intra-tumor heterogeneity of ER and HER2 expression in patients with ER-positive and HER2-positive breast cancer.
    Ju, Jie
    Du, Feng
    Gao, Songlin
    Si, Yiran
    Hu, Nanlin
    Liu, Dongxu
    Wang, Xue
    Yue, Jian
    Zheng, Fangchao
    Kang, Yikun
    Yang, Zixuan
    Ma, Fei
    Xu, Binghe
    Yuan, Peng
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] HER2 Gene Amplification in ER-positive HER2 Immunohistochemistry 0 or 1+Breast Cancer With Early Recurrence
    Yamashita, Hiroko
    Ishida, Naoko
    Hatanaka, Yutaka
    Hagio, Kanako
    Oshino, Tomohiro
    Takeshita, Takashi
    Kanno-Okada, Hiromi
    Shimizu, Ai
    Hatanaka, Kanako C.
    Matsuno, Yoshihiro
    ANTICANCER RESEARCH, 2020, 40 (02) : 645 - 652